THE PIPELINE PAPERS Issue No. 3

Dear Reader, This month’s intelligence concerns a mystery hiding in plain sight. Your pharma supply chain is emitting — and yet, most of the industry cannot say exactly how much. Allow us to illuminate.

The pharmaceutical sector’s Scope 3 emissions from purchased goods and services total over 272 million tCO₂e — representing more than 80% of total pharma Scope 3 (PSCI, 2025). And yet the data needed to measure this accurately barely exists. Generic databases do not reflect pharma-specific manufacturing grades. Supplier certificates arrive inconsistently. Manual literature searches take weeks. This season, dear reader, we ask the question the industry has been quietly avoiding: where do your material emission factors actually come from? And what can be done about it? Did you notice we have been talking about Eco Insight®?

📊 Act I: THE HIDDEN GIANT: WHY MATERIALS & CONSUMABLES ARE YOUR BIGGEST CARBON STORY

This author was somewhat aware. However, the numbers are, frankly, rather startling. For pharmaceutical companies, Category 1 (Purchased Goods and Services) alone represents the dominant share: across the sector, this figure has been calculated at over 272 million tCO₂e, representing more than 80% of total pharma Scope 3 (PSCI, 2025, Ref 1). That is the story.

High-volume consumables — microplates, pipette tips, culture vessels, single-use bioreactor assemblies, filters, resins, tubing — are frequent offenders. As Green Elephant Biotech noted in December 2025, these items “often account for a surprisingly large portion of Scope 3 emissions” — yet they rarely feature in early-stage sustainability assessments. The biopharmaceutical sector has spent years perfecting process mass intensity (PMI) as a proxy for environmental burden. But PMI measures mass efficiency, not carbon. Knowing that 1 kg of product consumed 500 kg of materials tells you nothing about whether those materials were made in a coal-heavy or renewables-rich region, or by a solvent-intensive or biocatalytic route.

Healthcare and pharma together account for 4.4% of global net emissions (Biopharm Services, 2025, Ref 2). As regulatory pressure intensifies — from CSRD ESRS E1 in Europe to investor-led ESG disclosure requirements globally — the question of material and consumable emission factors is moving rapidly from voluntary reporting curiosity to mandatory compliance territory. And yet the data infrastructure to support it has, until very recently, simply not existed at a pharma-specific level.

🔍  Act II:  THE DATA PROBLEM: WHY GENERIC DATABASES ARE NOT GOOD ENOUGH

The problem is structural. Generic LCA databases such as industry-wide emission factor registries are not built for biopharmaceutical manufacturing grades, supply chain configurations, or regional production routes. A CO₂e value for “Acetic Acid” in a generic database may reflect a chemical commodity process entirely unrelated to the pharmaceutical-grade material being purchased. As the Eco Insight® Use Case Guide (Biopharm Services, April 2026) identifies: “generic LCA databases do not reflect biopharmaceutical manufacturing methods, grades, or supply chains.” The gap is not a gap in effort — it is a gap in specificity.

The published effort to quantify single-use lab consumable carbon footprints through LCA-derived emission factors appeared only in 2023, in PLOS Sustainability and Transformation (Ragazzi et al., 2023, Ref 3).

That this milestone arrived so recently illustrates how early-stage pharma-specific material emission factor science remains. BioPhorum’s 2024 report “Developing a Harmonised Approach to Product Carbon Footprint Data for the Biopharma Industry” confirmed the same: a shared, validated data infrastructure for biopharma PCFs is still being built — and is urgently needed (BioPhorum / Sartorius, 2024, Ref 4).

The regulatory stakes are rising accordingly. ISO 14067 requires validated, traceable emission factors across the full product lifecycle. PAS 2090:2025 — the first internationally harmonised Product Category Rules for LCA of medicines — was published by BSI earlier this year, developed through the Pharmaceutical LCA Consortium (PEG Hub / EFPIA, 2025, Ref 5). The standard demands credible, consistent, science-based frameworks for measuring and comparing environmental performance across medicines.

🧪 Act III: ECO INSIGHT®: IMMEDIATE INTELLIGENCE, NO PLATFORM REQUIRED

Here is the rather good news. Eco Insight®, Biopharm Services’ newest tool, is designed precisely for this moment — and it requires no existing software licence, no BioSolve® Process license, and no prior relationship with Biopharm® Services. For sustainability managers, procurement teams, process development scientists, and consultants who need human reviewed and validated pharma-specific CO₂e emission factors, it is available as a standalone tool delivering immediate, actionable value (Eco Insight® Use Case Guide, Biopharm Services, April 2026, Ref ).

The workflow is elegantly simple. A Sustainability Manager preparing the annual GHG inventory for Scope 3 Category 1 accesses Eco Insight® and searches for their highest-spend biopharmaceutical materials. For each, they find validated CO₂e emission factors from multiple sources, with manufacturing process details relevant to pharmaceutical production. The AI Assistant can be queried in plain language — “What is the most appropriate CO₂e/kg value for Acetic Acid sourced from a European supplier using conventional industrial production?” — and responds with cited database records, regional and process differences, and a recommended defensible value. The full selection is documented with source citations and ISO 14067 compliance status for the audit trail. A Scope 3 Category 1 inventory that previously took weeks of manual research can be completed in days (Eco Insight® Use Case Guide, April 2026, Ref 6).

The value extends across several professional audiences. Procurement teams can compare two public domain sources of the same material — different manufacturing routes, different regions — and make decisions with carbon visibility. Regulatory affairs teams can produce a documented submission using an ISO 14067-compliant public-domain source document, if available. Consultants advising on facility design or tech transfer have a credible, citable source of pharma-specific CO₂e data to bring to client conversations. And for those who later wish to graduate to full in silico process emissions modelling, Eco Insight® is the natural gateway into the BioSolve® Process Application to estimate the Scope 1 and 2 emissions.

✨  Biopharm Services Spotlight

Eco Insight® is Biopharm Services’ purpose-built, pharma-specific, human-reviewed and validated CO₂e database for biopharmaceutical materials based on public domain sources — the new tool of its kind.

It provides multi-source, ISO 14067-labelled emission factors (where applicable) with full source transparency, along with an AI Assistant for rapid, cited, defensible data selection. Available as a standalone tool with User and Enterprise pricing — no BioSolve® Process licence required. Request your demonstration at Biopharm Services | Contact us.

Key References

1.  PSCI (Pharmaceutical Supply Chain Initiative). How Verified Tools Are Transforming Pharma’s Supply Chain. November 2025. https://pscinitiative.org/resource?resource=3037

2.  Biopharm Services. Integrating Eco-Design in Bioprocess Development. February 2025. https://biopharmservices.com/integrating-eco-design-in-bioprocess-development/

3.  PLOS Sustainability and Transformation. Using life cycle assessments to guide reduction in the carbon footprint of lab consumables. 2023. https://journals.plos.org/sustainabilitytransformation/article?id=10.1371/journal.pstr.0000080

4.  BioPhorum / Sartorius. Developing a harmonised approach to product carbon footprint data for the biopharma industry. February 2024. https://www.sartorius.com/download/1580096/biophorum-harmonized-approach-product-carbon-footprint-data-1–data.pdf

5.  PEG Hub / EFPIA. PAS 2090:2025 – Pharmaceutical Products: Product Category Rules for Environmental LCA. 2025. https://peghub.org/lca

6.  Eco Insight® Use Case Content Guide: BioSolve Process Users vs. Non-Users. Biopharm Services Ltd., April 2026. https://biopharmservices.com

Sources verified from publicly available industry news, trade publications, and company communications as of May 2026.

Some content is generated with the help of AI.

Until next season, dear reader — may your pipelines be plentiful and your carbon footprint decidedly slim.

XOXO,  The Pipeline Papers

A monthly LinkedIn newsletter by Biopharm Services  · biopharmservices.com